Combination Therapy May Combat Deadly Drug-Resistant Bacteria
Jacqueline Mitchell (BIDMC Communications) 617-667-7306, firstname.lastname@example.org
JULY 19, 2019
BIDMC researchers use innovative technique to repurpose existing antibioticsBecause bacteria – especially Gram-negative strains – are becoming increasingly resistant to current antibiotics, investigators are studying the potential of combining two or more drugs to work together to combat resistant bacterial pathogens. Investigators at Beth Israel Deaconess Medical Center (BIDMC) have now demonstrated that existing antibiotics, some of which have been in use for decades, may have potent activity against such strains when used in combination.
The work, published in Antimicrobial Agents and Chemotherapy, is based on an untreatable infection that killed a woman in Nevada in 2016. In this case, the pathogen that was resistant to all 26 antibiotics tested at the U.S. Centers for Disease Control and Prevention (CDC).
“The Nevada strain is a Gram-negative bacteria, which means it’s surrounded by two protective coatings or membranes that makes it impervious to most antibiotics,” explained senior author James E. Kirby, MD, Director of the Clinical Microbiology Laboratory at BIDMC. “Gram-negative species also have ‘sump pumps’ in their cell membranes to rid themselves of any antibiotics that make it through this already formidable barrier. We have been pursuing two strategies – combination therapy and repurposing of older antibiotics – to address the challenges posed by Gram-negative infections and, as soon as this pathogen became available for research experiments, we wanted to test whether these strategies would work against the otherwise untreatable Nevada strain.”
The study’s methods draw on the researchers’ previous findings that combination therapy may be effective even when bacteria become resistant to colistin, which is considered a treatment agent of last resort that can punch holes in the tough outer shell of Gram-negative bacteria. Kirby and Thea Brennan-Krohn, MD, a post-doctoral research fellow in Kirby’s lab, used a modified inkjet printer to test the activity of 20 antibiotic combinations, 18 of which contained colistin, against the Nevada strain. The inkjet technology dispenses uniform bacterial samples into each of the 96 wells in a standard lab testing plate to allow for rapid and consistent testing of different drug combinations.
Although none of the 26 antibiotics tested by the CDC worked by themselves against the Nevada strain, the researchers saw synergy when colistin was combined with 21 antibiotics assayed. Most drugs were effective in combinations when used in standard doses. Also, no combinations demonstrated antagonism, or interference with each other.
“Although more evaluation is needed to find out if these combinations would be effective for patients, their activity at low concentrations in the lab is promising, suggesting that they may have clinical activity at levels that are not toxic,” said Brennan-Krohn.
Interestingly, some agents that are active against organisms such as Staphylococcus aureus (including the antibiotic resistant version of this bacteria, called MRSA) but are not normally active against Gram-negative bacteria, showed potent activity against the Nevada strain when combined with colistin. “Our hypothesis is that colistin pokes holes in the Gram-negative membrane, allowing these antibiotics to get into the bacterial cytoplasm, where they are effective,” said Brennan-Krohn.
If results continue to look promising in additional studies, it could mean that physicians already have access to effective treatment options for patients with potentially deadly and resistant bacterial infections.
The work was supported by Boston Children’s Hospital, the National Institute of Allergy and Infectious Diseases (K08AI132716), and the National Institute of Allergy and Infectious Diseases (R21AI146485 and R21AI142040). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The HP D300 digital dispenser used in synergy analysis was provided by Tecan (Morrisville, NC). Tecan had no role in study design, data collection/interpretation, manuscript preparation, or decision to publish.
About Beth Israel Deaconess Medical Center
Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School and consistently ranks as a national leader among independent hospitals in National Institutes of Health funding.
BIDMC is in the community with Beth Israel Deaconess Hospital-Milton, Beth Israel Deaconess Hospital-Needham, Beth Israel Deaconess Hospital-Plymouth, Anna Jaques Hospital, Cambridge Health Alliance, Lawrence General Hospital, Signature Healthcare, Beth Israel Deaconess HealthCare, Community Care Alliance and Atrius Health. BIDMC is also clinically affiliated with the Joslin Diabetes Center and Hebrew Rehabilitation Center and is a research partner of Dana-Farber/Harvard Cancer Center and the Jackson Laboratory. BIDMC is the official hospital of the Boston Red Sox. For more information, visit www.bidmc.org.
BIDMC is part of Beth Israel Lahey Health, a new health care system that brings together academic medical centers and teaching hospitals, community and specialty hospitals, more than 4,000 physicians and 35,000 employees in a shared mission to expand access to great care and advance the science and practice of medicine through groundbreaking research and education.